Paratek Pharma Reports Full Year And Fourth Quarter 2016 Financial Results And Provides Clinical Update Post author:Sam Post published:March 1, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Patient Death Forces Alnylam to Suspend Dosing in Hemophilia Trial, Stock Plunges September 6, 2017 Marrone Bio Innovations, Inc Closes $9.2 Million Public Offering Of Common Stock With Full Exercise Of Over-Allotment Option April 30, 2017 <b>Spruce Biosciences</b> Provides Corporate Update On Series A Venture Financing, Leadership Team And Lead Clinical Program October 11, 2017
Marrone Bio Innovations, Inc Closes $9.2 Million Public Offering Of Common Stock With Full Exercise Of Over-Allotment Option April 30, 2017
<b>Spruce Biosciences</b> Provides Corporate Update On Series A Venture Financing, Leadership Team And Lead Clinical Program October 11, 2017